![]() |
市場調查報告書
商品編碼
1941880
內視鏡黏膜下剝離術 (ESD) 市場規模、佔有率和趨勢分析報告:按產品、適應症、最終用途、地區和細分市場預測 (2026-2033)Endoscopic Submucosal Dissection Market Size, Share & Trends Analysis Report By Product (Gastroscopes And Colonoscopes), By Indication (Stomach Cancer), By End Use (Hospitals), By Region, And Segment Forecasts, 2026 - 2033 |
||||||
全球內視鏡黏膜下剝離術 (ESD) 市場預計到 2025 年將達到 3.915 億美元,預計到 2033 年將達到 5.9758 億美元。
預計2026年至2033年的複合年成長率為5.40%。消化器官系統癌症及其他相關疾病的日益普遍,以及內視鏡技術和儀器的進步,正在推動對ESD等診斷和治療程序的需求。
例如,根據美國癌症協會的估計,預計到2026年1月,全球將新增31510例胃癌病例,其中女性13610例,男性17900例。隨著食道癌、胃癌和大腸直腸癌的發生率在全球範圍內持續上升,對內視鏡黏膜下剝離術(ESD)等先進治療方法的需求也日益成長。
內視鏡黏膜下剝離術 (ESD) 市場涵蓋了主要用於整塊切除胃腸道(GI)淺層腫瘤性病變的先進內視鏡手術,特別適用於食道、胃和大腸。與通常適用於小型病灶的內視鏡黏膜下剝離術 (EMR) 不同,ESD 可透過精確剝離黏膜下層,完整切除較大且更複雜的病灶。此手術使用 ESD 刀、黏膜下注射液、止血器械和高解析度內視鏡等專用器械。 ESD 在早期胃腸道癌症的治療中發揮著至關重要的作用,可實現更高的根治性切除率、更佳的病理評估以及器官功能的保留。
隨著世界人口老化,內視鏡黏膜下剝離術(ESD)的需求日益成長。人口老化預計會導致包括癌症在內的老齡化相關消化系統疾病發生率上升。根據美國癌症協會(2026年1月報告),胃癌主要影響老年人,平均確診年齡為68歲,每年確診患者中約有60%為65歲以上。許多老年患者也伴隨其他健康問題,使得傳統手術風險更高,也進一步加劇了ESD手術的需求。
內視鏡黏膜下剝離術 (ESD) 市場的成長主要受胃腸道癌症 (GI 癌症) 負擔加重的推動。主要的胃腸道癌症包括大腸直腸癌、胃癌、食道癌和胰腺癌。長期胃食道逆流症 (GERD)、遺傳性疾病、胃部感染疾病、慢性胃炎、息肉的存在等因素均會增加胃癌的風險。根據美國癌症協會 (ACS) 預測,到 2024 年,美國將新增 152,810 例大腸直腸癌病例,其中結腸癌 106,590 例,直腸癌 46,220 例。大腸直腸癌也是全國第二大癌症相關死亡原因,預計到 2024 年將有 53,010 人死於此病。胃腸道癌症患者的這種成長趨勢顯著推動了對先進的微創治療方法(如內視鏡黏膜下剝離術 (ESD))的需求,這些治療可提供更高的根治性切除率和更好的患者預後。
醫療專業人員對內視鏡黏膜下剝離術(ESD)技術的認知度不斷提高,培訓計畫的拓展也促進了市場成長。胃腸病學家和外科醫生ESD技術水平的提升,擴大了這項先進手術的應用範圍和可行性,尤其是在以往此類治療資源有限的地區。眾多醫療機構提供專業的培訓和認證項目,這對掌握ESD知識和技能至關重要。例如,富士膠片醫療歐洲有限公司於2024年4月推出了“EndoGel”,這是一款用於掌握內視鏡肌切開術(POEM)和內視鏡黏膜下剝離術(ESD)技術的創新培訓模型。該模擬器有兩個版本:“EndoGel for ESD/POEM”和“EndoGel for ESD”,旨在為內視鏡專家和醫療機構提供經濟高效的培訓。透過逼真的模擬訓練,EndoGel旨在提高操作者的熟練度和患者的治療效果。
人工智慧 (AI) 預計將在未來的內視鏡黏膜下剝離術 (ESD) 市場中發揮日益重要的作用,其關鍵在於提高病灶檢測、定性和治療計劃的準確性。 AI 驅動的影像分析和即時決策支援系統能夠幫助內視鏡醫師準確識別病灶邊界、評估浸潤深度並最佳化切除策略。此外,將 AI 整合到機器人和內視鏡平台中,可提高手術的準確性、一致性和療效,同時也有助於培訓並降低對操作者的依賴性。隨著 AI 驅動的內視鏡技術的不斷成熟,預計臨床效率將得到提升,治療結果的差異性將降低,先進的 ESD 手術也將得到更廣泛的應用。
The global endoscopic submucosal dissection market size was estimated at USD 391.50 million in 2025 and is projected to reach USD 597.58 million by 2033, growing at a CAGR of 5.40% from 2026 to 2033. The increasing prevalence of gastrointestinal cancers and other related disorders, and advancements in endoscopic technology & instrumentation, drive the demand for diagnostic and therapeutic procedures such as ESD.
For instance, the American Cancer Society estimates that in January 2026, there will be 31,510 new cases of stomach cancer, with 13,610 cases in women and 17,900 cases in men. As esophageal, gastric, and colorectal cancer rates continue to rise globally, the need for advanced procedures, such as ESD, is increasing.
The endoscopic submucosal dissection (ESD) market encompasses an advanced endoscopic procedure used mainly for en bloc removal of superficial neoplastic lesions within the gastrointestinal (GI) tract, particularly in the esophagus, stomach, and colon. In contrast to endoscopic mucosal resection (EMR), which is generally suited for smaller lesions, ESD allows for the complete resection of larger and more complex lesions through precise dissection of the submucosal layer. The procedure relies on specialized tools, including ESD knives, submucosal injection solutions, hemostatic devices, and high-definition endoscopes. ESD plays a critical role in the management of early-stage GI cancers, offering higher curative resection rates, improved pathological evaluation, and preservation of organ integrity.
The aging population worldwide is boosting the demand for ESD. As the global population ages, age-related gastrointestinal conditions, including cancers, are expected to rise. According to the American Cancer Society in January 2026, gastric cancer predominantly affects older individuals, with an average age of 68 when diagnosed, and 6 out of 10 diagnosed annually are 65 or older. Many older patients also have other health conditions, which make traditional surgery riskier, further contributing to the rising demand for ESD procedures.
The growth of the endoscopic submucosal dissection (ESD) market is driven by the rising burden of gastrointestinal (GI) cancers. Key GI cancer types include colorectal, gastric, esophageal, and pancreatic cancers. Factors such as long-standing gastroesophageal reflux disease (GERD), hereditary conditions, gastric infections, chronic gastritis, and the presence of polyps increase the risk of stomach cancer. According to the American Cancer Society (ACS), 152,810 new colorectal cancer cases are expected in the U.S. in 2024, including 106,590 colon cancer cases and 46,220 rectal cancer cases. Colorectal cancer also remains the second leading cause of cancer-related deaths in the country, with an estimated 53,010 deaths projected in 2024. This growing prevalence of GI cancers is significantly driving the demand for advanced, minimally invasive treatments such as ESD, which offer higher curative resection rates and better patient outcomes.
The growing awareness and training programs for healthcare professionals in ESD techniques contribute to market growth. The proficiency of gastroenterologists and surgeons in ESD has been increasing, enhancing both the reach and feasibility of this advanced procedure, particularly in areas that previously had limited access to such treatments. Various medical organizations offer specialized training and certification programs, which are important in gaining knowledge and expertise in ESD. For instance, in April 2024, FUJIFILM Healthcare Europe GmbH introduced EndoGel, an innovative training model designed for performing Peroral Endoscopic Myotomy (POEM) and Endoscopic Submucosal Dissection (ESD) procedures. This simulator is available in two versions such as EndoGel for ESD/POEM and EndoGel for ESD. It is designed to be cost effective for endoscopy professionals and healthcare institutions, aiming to enhance proficiency and patient outcomes through realistic simulation training.
Artificial intelligence (AI) is expected to play an increasingly important role in the future of the ESD market by enhancing lesion detection, characterization, and procedural planning. AI-powered image analysis and real-time decision-support systems can assist endoscopists in accurately identifying lesion margins, assessing invasion depth, and optimizing resection strategies. Furthermore, AI integration with robotic and endoscopic platforms can improve procedural precision, consistency, and outcomes, while supporting training and reducing operator dependency. As AI-enabled endoscopy continues to mature, it is likely to improve clinical efficiency, reduce variability in outcomes, and further expand the adoption of advanced ESD procedures.
Global Endoscopic Submucosal Dissection Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the endoscopic submucosal dissection market on the basis of product, indication, end use, and regions.